ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2025.91.05ymj-1618Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHПерспективы выявления рака яичников при генетическом исследовании аспирата из полости маткиProspects for the detection of ovarian cancer by genetic testing of aspirate from the uterine cavityhttps://orcid.org/0009-0005-8204-705XГрафскаяМ. Ю.GrafskayaM. Yu.

Графская Мария Юрьевна – к.м.н., докторант.

344037, Ростов-наДону, 14-я линия, 63

mariagrafskaja@ya.ruhttps://orcid.org/0000-0002-1084-5176ВереникинаЕ. В.VerenikinaE. V.

Вереникина Екатерина Владимировна – д.м.н., зав. Отделением.

344037, Ростов-наДону, 14-я линия, 63

ekat.veren@yandex.ruhttps://orcid.org/0000-0002-1397-837XМаксимовА. Ю.MaksimovA. Yu.

Максимов Алексей Юрьевич – д.м.н., проф., зам. ген. Директора.

344037, Ростов-наДону, 14-я линия, 63

rnioi@list.ruhttps://orcid.org/0000-0003-3545-9359ДемидоваА. А.DemidovaA. A.

Демидова Александра Александровна – д.м.н., доцент, зав. Кафедрой.

344022, Ростов-на-Дону, пер. Нахичеванский, 29

alald@inbox.ruhttps://orcid.org/0009-0008-3611-6749БоваЕ. В.BovaE. V.

Бова Елена Викторовна – к.м.н., доцент.

344022, Ростов-на-Дону, пер. Нахичеванский, 29

bova_ev@rostgmu.ruНажеваМ. И.NazhevaM. I.

Нажева Марина Ибрагимовна – к.м.н., доцент.

344022, Ростов-на-Дону, пер. Нахичеванский, 29

nazheva@mail.ruhttps://orcid.org/0000-0002-9374-6009ДубатоваИ. В.DubatovaI. V.

Дубатова Ирина Владимировна – к.м.н., доцент.

344022, Ростов-на-Дону, пер. Нахичеванский, 29

dubatovaiv@mail.ruФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава РоссииRussian FederationФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииRussian Federation202522092025032428Copyright © Графская М.Ю., Вереникина Е.В., Максимов А.Ю., Демидова А.А., Бова Е.В., Нажева М.И., Дубатова И.В., 20252025Графская М.Ю., Вереникина Е.В., Максимов А.Ю., Демидова А.А., Бова Е.В., Нажева М.И., Дубатова И.В.Grafskaya M.Y., Verenikina E.V., Maksimov A.Y., Demidova A.A., Bova E.V., Nazheva M.I., Dubatova I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/1618

В статье у больных серозной карциномой яичников проведено генетическое исследование биологических образцов из аспирата полости матки с целью выявления мутаций генов, характерных для опухолевого поражения яичников. Доказано, что в аспирате из полости матки присутствуют диагностически значимые количества клеток или фрагментов клеток рака яичников, необходимых для проведения молекулярно-генетического анализа и обнаружения мутаций генов TP53, FAT3, CSMD3, BRAF, KRAS. Мутации генов BRCA1/2 встречаются редко. Обнаружение мутаций генов TP53, FAT3, CSMD3, BRAF, KRAS в клетках аспирата из полости матки требует проведения активного диагностического поиска в отношении выявления серозной карциномы яичников.

In the article, a genetic study of biological samples from uterine cavity aspirate was performed in patients with serous ovarian carcinoma in order to identify gene mutations characteristic of ovarian tumor lesions. It has been proven that the aspiration from the uterine cavity contains diagnostically significant numbers of cells or fragments of ovarian cancer cells necessary for molecular genetic analysis and detection of mutations in the TP53, FAT3, CSMD3, BRAF, and KRAS genes. Mutations of the BRCA1/2 genes are rare. The detection of TP53, FAT3, CSMD3, BRAF, and KRAS gene mutations in uterine aspirate cells requires an active diagnostic search for the detection of ovarian serous carcinoma.

рак яичниковсерозная карциномаморбидное ожирениеонкогенные мутацииаспирационная биопсияovarian cancerserous carcinomamorbid obesityoncogenic mutationsaspiration biopsyReferencesВозможности скрининга рака тела матки по содержанию молекулярных маркеров в моче и вагинально-цервикальном секрете / О.И. Кит [и др.] // Клиническая лабораторная диагностика. 2023. No 3(68). 141-145. doi: 10.51620/0869-2084-2023-68-3-141-145Рossibilities of screening for cancer of the uterine body by the content of molecular markers in urine and vaginal-cervical secretion. / Kit O.I. [et al] // Russian Clinical Laboratory Diagnostics. 2023. No 68 (3). 141-145. doi: 10.51620/0869-2084-2023-68-3-141-145Савинова А.Р., Гатауллин И.Г. Ранняя диагностика и скрининг рака яичников // Казанский медицинский журнал. 2022. № 3 (103). С. 476-483. doi: 10.17816/KMJ2022-476.Savinova A.R., Gataullin I.G. Early diagnostics and screening for ovarian cancer. // Kazan medical journal. 2022. № 3 (103). С. 476-483.Al-Moghrabi N., et al. Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and HighGrade Serous Ovarian Cancer in Saudi Women. Int J Mol Sci. 2024 Mar 7. No 25(6). 3108. doi: 10.3390/ijms25063108.Al-Moghrabi N., et al. Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and HighGrade Serous Ovarian Cancer in Saudi Women. Int J Mol Sci. 2024 Mar 7. No 25(6). 3108. doi: 10.3390/ijms25063108.Talhouk A., et al. Development and validation of the gene expression predictor of highgrade serous ovarian carcinoma molecular SubTYPE (PrOTYPE). Clin. Cancer Res. 2020. 26. 5411–5423. doi: 10.1158/1078-0432.CCR-20-0103.Talhouk A., et al. Development and validation of the gene expression predictor of highgrade serous ovarian carcinoma molecular SubTYPE (PrOTYPE). Clin. Cancer Res. 2020. 26. 5411–5423. doi: 10.1158/1078-0432.CCR-20-0103.Heitz F., et al. Dilution of molecular-pathologic gene signatures by medically associated factors might prevent prediction of resection status after debulking surgery in patients with advanced ovarian cancer. Clin. Cancer Res. 2020. No 26. 213–219. doi: 10.1158/1078-0432.CCR-19-1741. doi: 10.1016/j.bpobgyn.2020.02.010Heitz F., et al. Dilution of molecular-pathologic gene signatures by medically associated factors might prevent prediction of resection status after debulking surgery in patients with advanced ovarian cancer. Clin. Cancer Res. 2020. No 26. 213–219. doi: 10.1158/1078-0432.CCR-19-1741. doi: 10.1016/j.bpobgyn.2020.02.010Kinde I., et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl. Med. 2013. No 5. 167ra4.Kinde I., et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl. Med. 2013. No 5. 167ra4.Friedenreich C.M., Ryder-Burbidge C., McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol. Oncol. 2021. No 15. 790–800 (2021). doi: 10.1002/1878-0261.12772.Friedenreich C.M., Ryder-Burbidge C., McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol. Oncol. 2021. No 15. 790–800 (2021). doi: 10.1002/1878-0261.12772.Gaona-Luviano P., Medina-Gaona L.A., Magaña-Pérez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020. No 9(4). 47. doi: 10.21037/cco-20-34.Gaona-Luviano P., Medina-Gaona L.A., Magaña-Pérez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020. No 9(4). 47. doi: 10.21037/cco-20-34.Ramachandran D., et al. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease. NPJ Genom. Med. 2024. No 9. 19 (2024). doi: 10.1038/s41525-024-00395-yRamachandran D., et al. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease. NPJ Genom. Med. 2024. No 9. 19 (2024). doi: 10.1038/s41525-024-00395-yCafforio P., et al. Liquid biopsy in cervical cancer: hopes and pitfalls. Cancers. 2021. No 13. 3968. DOI: 10.3390/cancers13163968.Cafforio P., et al. Liquid biopsy in cervical cancer: hopes and pitfalls. Cancers. 2021. No 13. 3968. DOI: 10.3390/cancers13163968.Nash Z., Menon U. Ovarian cancer screening: current status and future directions. Best Pract. Res. Clin. Obstet. Gynaecol. 2020. No 65. 32–45.Nash Z., Menon U. Ovarian cancer screening: current status and future directions. Best Pract. Res. Clin. Obstet. Gynaecol. 2020. No 65. 32–45.Hanley G.E., et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open. 2022 Feb1. No 5(2). e2147343. doi: 10.1001/jamanetworkopen.2021.47343.Hanley G.E., et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open. 2022 Feb1. No 5(2). e2147343. doi: 10.1001/jamanetworkopen.2021.47343.Potenza E., et al. Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer. Int J Biol Markers. 2020. No 35(4). 20–27. doi: 10.1177/1724600820955195.Potenza E., et al. Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer. Int J Biol Markers. 2020. No 35(4). 20–27. doi: 10.1177/1724600820955195.Gersekowski K., et al. Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis. Cancer Epidemiol Biomarkers Prev. 2024 Apr 3. No 33(4). 586-592. doi: 10.1158/1055-9965.Gersekowski K., et al. Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis. Cancer Epidemiol Biomarkers Prev. 2024 Apr 3. No 33(4). 586-592. doi: 10.1158/1055-9965.Funston G., et al. The diagnostic performance of CA-125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020. 17(10). e1003295. doi: 10.1371/journal.pmed.1003295.Funston G., et al. The diagnostic performance of CA-125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020. 17(10). e1003295. doi: 10.1371/journal.pmed.1003295.Webb P.M., Jordan S.J. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024 May; No 21(5). 389-400. doi: 10.1038/s41571-024-00881-3.Webb P.M., Jordan S.J. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024 May; No 21(5). 389-400. doi: 10.1038/s41571-024-00881-3.

The authors declare that there are no conflicts of interest present.